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Abstract. Acute caffeine administration increases cortisol and converts the 
dexamethasone suppression test (DST) to nonsuppression in normal humans; 
data concerning chronic administration as well as effects in depressed patients are 
minimal. To determine whether caffeine intake influenced DST results in 
depression, we retrospectively studied the relationship between regular daily 
caffeine consumption and pretreatment DST status in major depressives. Daily 
intake was not correlated with either post-DST cortisol levels or symptom 
ratings. These data suggest that chronic caffeine use is unlikely to be a major 
factor in dysregulation of the hypothalamic-pituitary-adrenal axis in depression, 
perhaps because of the development of tolerance. 
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Acute caffeine administration increases cortisol in animals (Spindel et al., 1983) and 
humans (Spindel et al., 1984; Uhde et al., 1984; Charney et al., 1985). Uhde et al. 
(1985) reported the conversion of dexamethasone suppression test (DST) suppres- 
sors to nonsuppressors by giving oral caffeine 1.5 to 2 hours before 4 p.m. post-DST 
blood sampling in a small sample of depressed patients and normal controls. 
Greden et al. (1978) reported that more severely depressed patients used more 
caffeine, possibly to elevate depressed mood. Therefore, if regular caffeine ingestion 
also affects the hypothalamic-pituitary-adrenal (HPA) axis in the same way that 
acute administration does, daily caffeine intake might influence DST findings in 
depression. However, a study in animals (Spindel et al. 1983) showed that with 
chronic caffeine administration tolerance developed to caffeine’s cortisol-stimulating 
effect. Also, higher doses of caffeine seemed to be required to stimulate cortisol 
release (Spindel et al., 1984) than doses that produce behavioral changes (Snyder 
and Sklar, 1984) or catecholamine release (Robertson et al., 1981) in humans. 
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Thus, we examined the relationship between pretreatment DST status and 
retrospective self-report of daily caffeine consumption in a large sample of people 
with major depression. If chronic caffeine use influences DST status, we might 
expect higher caffeine use in DST nonsuppressors. 
Methods 
One hundred and twenty-one major depressives, defined according to Research Diagnostic 
Criteria (RDC) (Spitzer et al., 1978) (mean + SD age = 40.0 + 13.4 years; range 20-83 years; 
42 males; 90 unipolars; 45 inpatients), completed a caffeine questionnaire (Victor et al., 198 I) 
and the State-Trait Anxiety Inventory (Spielberger et al., 1970). Experienced clinicians 
evaluated all patients with the I7-item version of the Hamilton Rating Scale for Depression 
(HRSD) (Hamilton, 1960). Anxiety was evaluated because many depressed patients report 
symptoms of anxiety, and anxiety has been shown to influence caffeine intake (Lee et al., 
1985); thus, anxiety might be a relevant factor in interpreting results. The caffeine ques- 
tionnaire assessed amount of daily caffeine intake from approximately 25 sources, and also 
inquired about subjective symptom responses to ingesting one cup of coffee, as well as use of 
other drugs such as minor tranquilizers, antidepressants, hypnotics, and diet pills. Caffeine 
consumption was determined on the basis of usual daily use outside of the hospital. Although 
coffee and tea were freely available in the hospital setting, it is possible that caffeine use 
changed during hospitalization; therefore, inpatients were compared to outpatients (below). 
Pretreatment DSTs were done with I mg of dexamethasone administered orally at I I p.m., 
and blood sampling for plasma cortisol levels at 8 a.m., 4 p.m., or I I p.m. the next day. At 
least two blood samples were drawn from each patient; levels of plasma cortisol > 5 pg/dl in 
at least one sample constituted DST nonsuppression. Plasma cortisol was assayed by the 
competitive protein binding method (Murphy, 1967); interassay and intra-assay coefficients of 
variation were 7.2% and 7.070, respectively. 
Depressives were divided into two groups according to DST outcome (suppressor or 
nonsuppressor). Caffeine intake was compared across all patients; patients were also divided 
into three groups on the basis of their caffeine intake: low (O-249 mg/day), moderate (250-749 
mg/day), and high (2 750 mg/day) (Victor et al., 1981). Possible relationships between 
caffeine intake with post-DST cortisol levels and symptom severities were examined. Reports 
of subjective symptom responses to caffeine intake were compared between groups. Because 
of positive skewness of the distributions, log-transformed values were used for caffeine 
consumption and post-DST cortisol values. Statistical tests included x2, Pearson product- 
moment correlations, and analyses of variance and covariance. 
Results 
Mean (+ SD) daily caffeine consumption for all subjects was reported to be 393 + 
415 mg/day (range: 6-2289 mg); 49.6% were low consumers, 31.4% were moderate 
consumers, and 19.0% were high consumers. There were no significant correlations 
between caffeine intake and actual cortisol levels at any postdexamethasone time 
point, either for the total sample or for any of the three caffeine intake groups. There 
was no significant difference in percentage of subjects in the three caffeine intake 
groups between DST suppressors (n = 85) and nonsuppressors (n = 36) whether 
calculated on the basis of postdexamethasone 4 p.m. level or on the basis of 
maximum postdexamethasone determination (Table I). However, after removing by 
covariance differences in age and depression (H RSD) scores that have been reported 
to influence caffeine intake (Greden et al., 1978), there was a trend toward increased 
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caffeine intake in DST suppressors (adjusted means: 412 mg vs. 349 mg, p < 0.07). 
There were no differences in use of other drugs between groups. DST suppressors 
were significantly younger than nonsuppressors (means: 37.9 vs. 47.0 years, 
p < 0.001). 
Table 1. Dexamethasone suppression test (DST) percentages positive and 
neoative at different caffeine intakes 
Daily caffeine intake (mg from all sources) 
Low (< 250) Moderate (250-749) High (> 750) 
DST negative (%) 45.9 (n = 39) 36.5 (n = 31) 17.6 (n = 15) 
DST positive (%) 61.1 (n = 22) 16.7 (n = 6) 22.2 (n = 6) 
by x2. p = 0.096 (highest postdexamethasone cortisol level) 
DST negative (%) 46.0 (n = 40) 34.5 (n = 30) 19.5 (II = 17) 
DST positive (%) 62.5 (n = 20) 16.6 (n = 6) 16.6 (n = 6) 
by x2, p = 0.203 (1600h postdexamethasone cortisol level) 
DST suppressors were somewhat less depressed than nonsuppressors, as indicated 
by the HRSD (means: 18.0 vs. 20.02) but somewhat more anxious, as indicated by 
the trait part of the Spielberger inventory (means: 59.4 vs. 54.0); state anxiety 
showed no difference. There were no differences in depression or anxiety (state or 
trait) across the three caffeine intake groups. There were no significant associa- 
tions between reported daily caffeine intake and any symptom ratings, either in the 
total sample or separately for suppressors and nonsuppressors (see Table 2 for list of 
symptoms). 
In response to ingesting a cup of coffee, 43.3% of suppressors but only 21.6% of 
nonsuppressors reported experiencing anxiety k* test, p < 0.02). Suppressors also 
reported more of the other symptoms including “lightheadedness” @ < 0.05) and 
“tachycardia” (p < 0.0 1) (Table 2). There were no significant differences in caffeine’s 
mood-elevating (“cheer up,” “less depressed, ” “well being”) effect between the two 
groups (Table 2). 
Because all subjects were instructed to rate themselves on the caffeine ques- 
tionnaire based on an average day outside of the hospital over an unspecified period 
of time, and caffeine intake might have changed during hospitalization, all inpatients 
were compared to all outpatients. Inpatients had a higher percentage of 
nonsuppressors, based on the maximum postdexamethasone level (42.2% vs. 22.4$!& 
by x* test, p < 0.03) or based on the 4 p.m. level (40.9% vs. 18.7%; by x* test, 
p < 0.01) and inpatients were significantly older (means: 44.9 vs. 36.8 years, 
p < 0.001). However there were no differences in caffeine intake or in depression or 
anxiety scores, and only a small proportion of the symptoms (12%) differed 
significantly between the groups. 
Discussion 
Daily caffeine intake in major depressives was similar to intake previously reported 
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Table 2. Percentages of dexamethasone suppression test (DST) 
suppressors and nonsuppressors reporting subjective symp- 
toms in response to ingestion of one cup of coffee 
DST DST 
suppressors nonsuppressors P 
(n = 85) (n = 36) values 
Anxiety 43.3% 21.6% < 0.02’ 
Diarrhea 12.2 8.1 NS 
Diuresis 80.0 69.4 NS 
Headache 5.6 0.0 NS 
Lightheadedness 16.7 2.7 < 0.052 
Palpitation 18.9 10.8 NS 
Stomachache 15.6 18.9 NS 
Spot in front of eye 2.2 2.7 NS 
Tachycardia 32.2 10.8 < 0.013 
Tachypnea 5.6 2.7 NS 
Tremulousness 22.5 19.4 NS 
Cheer up 16.7 10.8 NS 
Less depressed 17.8 16.7 NS 
Well-being 33.7 24.3 NS 
1.x2 = 5.86. 
2.x2 = 5.36. 
3.x* = 7.04. 
in medical (Victor et al., 1981) and psychiatric (Greden et al., 1978) inpatients. 
Contrary to prediction, on the basis of retrospective reports, DST suppressors 
tended to use more caffeine than nonsuppressors, but the difference was small. These 
results suggest that chronic caffeine use produces tolerance to the acute effects of 
caffeine on the HPA axis, and thus that chronic caffeine use does not strongly 
influence DST status in depressed patients. 
The data collected in this study allowed us also to address the issue of the 
relationship between anxiety and the DST in depressed individuals. There have been 
conflicting results in prior studies-either higher anxiety in nonsuppressors, or no 
difference (Jimerson et al., 1983; Klein et al., 1984; Sangal et al., 1984; Kocsis et al,, 
1985; Roy et al., 1986; Grunhaus et al., 1987) which might be due in part to the use 
of different instruments to measure anxiety. Our finding of no difference in state 
anxiety between suppressors and nonsuppressors is consistent with the report of 
Sangal et al. (1984), who used the same state anxiety measure. The small increase in 
this study in trait anxiety in suppressors also suggests that there is no substantial 
difference between suppressors and nonsuppressors. Thus, the results of this study 
support the view that there is no difference in anxiety between suppressors and 
nonsuppressors. 
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